Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2018. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3693242011 | Product containing precisely fluocinolone acetonide 250 microgram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release cutaneous ointment (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3693243018 | Fluocinolone acetonide 250 microgram/g and neomycin sulfate 5 mg/g cutaneous ointment | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 4713271000005113 | fluocinolonacetonid 0,025 % + neomycinsulfat 0,5 % salve | da | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | Danish module (core metadata concept) |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing precisely fluocinolone acetonide 250 microgram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release cutaneous ointment (clinical drug) | Is a | kombinationspræparater med neomycin | false | Inferred relationship | Some | ||
| Product containing precisely fluocinolone acetonide 250 microgram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release cutaneous ointment (clinical drug) | Is a | Product containing fluocinolone (medicinal product) | false | Inferred relationship | Some | ||
| Product containing precisely fluocinolone acetonide 250 microgram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release cutaneous ointment (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Antiinfektiøst middel til huden | false | Inferred relationship | Some | ||
| Product containing precisely fluocinolone acetonide 250 microgram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release cutaneous ointment (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Neomycin (substance) | false | Inferred relationship | Some | ||
| Product containing precisely fluocinolone acetonide 250 microgram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release cutaneous ointment (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Fluocinolone (substance) | false | Inferred relationship | Some | ||
| Product containing precisely fluocinolone acetonide 250 microgram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release cutaneous ointment (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Corticosterone | false | Inferred relationship | Some | ||
| Product containing precisely fluocinolone acetonide 250 microgram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release cutaneous ointment (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | binyrehormonmiddel | false | Inferred relationship | Some | ||
| Product containing precisely fluocinolone acetonide 250 microgram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release cutaneous ointment (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Local anti-infective | false | Inferred relationship | Some | ||
| Product containing precisely fluocinolone acetonide 250 microgram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release cutaneous ointment (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Baktericid | false | Inferred relationship | Some | ||
| Product containing precisely fluocinolone acetonide 250 microgram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release cutaneous ointment (clinical drug) | Is a | Product containing fluocinolone and neomycin (medicinal product) | false | Inferred relationship | Some | ||
| Product containing precisely fluocinolone acetonide 250 microgram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release cutaneous ointment (clinical drug) | Has manufactured dose form | kutan OG/ELLER transdermal doseringsform | false | Inferred relationship | Some | ||
| Product containing precisely fluocinolone acetonide 250 microgram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release cutaneous ointment (clinical drug) | Has manufactured dose form | A semi-solid dose form consisting of a single-phase in which solids or liquids may be dissolved or dispersed in the base, which may be hydrophilic, hydrophobic or water-emulsifying. | false | Inferred relationship | Some | ||
| Product containing precisely fluocinolone acetonide 250 microgram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release cutaneous ointment (clinical drug) | Is a | Product containing fluocinolone in topical dosage form | false | Inferred relationship | Some | ||
| Product containing precisely fluocinolone acetonide 250 microgram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release cutaneous ointment (clinical drug) | Has manufactured dose form | Cutaneous ointment | true | Inferred relationship | Some | ||
| Product containing precisely fluocinolone acetonide 250 microgram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release cutaneous ointment (clinical drug) | Is a | neomycin til topikal anvendelse | false | Inferred relationship | Some | ||
| Product containing precisely fluocinolone acetonide 250 microgram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release cutaneous ointment (clinical drug) | Has concentration strength denominator value | en | false | Inferred relationship | Some | 1 | |
| Product containing precisely fluocinolone acetonide 250 microgram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release cutaneous ointment (clinical drug) | This attribute specifies the denominator unit for the concentration strength of a product. | g | true | Inferred relationship | Some | 1 | |
| Product containing precisely fluocinolone acetonide 250 microgram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release cutaneous ointment (clinical drug) | Has concentration strength denominator value | en | false | Inferred relationship | Some | 2 | |
| Product containing precisely fluocinolone acetonide 250 microgram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release cutaneous ointment (clinical drug) | Count of base of active ingredient | to | false | Inferred relationship | Some | ||
| Product containing precisely fluocinolone acetonide 250 microgram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release cutaneous ointment (clinical drug) | This attribute specifies the denominator unit for the concentration strength of a product. | g | true | Inferred relationship | Some | 2 | |
| Product containing precisely fluocinolone acetonide 250 microgram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release cutaneous ointment (clinical drug) | The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). | Fluocinolone acetonide (substance) | true | Inferred relationship | Some | 1 | |
| Product containing precisely fluocinolone acetonide 250 microgram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release cutaneous ointment (clinical drug) | This attribute specifies the numerator unit for the concentration strength of a product. | mcg | true | Inferred relationship | Some | 1 | |
| Product containing precisely fluocinolone acetonide 250 microgram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release cutaneous ointment (clinical drug) | This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. | Neomycin sulfate | true | Inferred relationship | Some | 2 | |
| Product containing precisely fluocinolone acetonide 250 microgram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release cutaneous ointment (clinical drug) | Has concentration strength numerator value | 250 | false | Inferred relationship | Some | 1 | |
| Product containing precisely fluocinolone acetonide 250 microgram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release cutaneous ointment (clinical drug) | This attribute specifies the numerator unit for the concentration strength of a product. | mg | true | Inferred relationship | Some | 2 | |
| Product containing precisely fluocinolone acetonide 250 microgram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release cutaneous ointment (clinical drug) | The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). | Neomycin sulfate | true | Inferred relationship | Some | 2 | |
| Product containing precisely fluocinolone acetonide 250 microgram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release cutaneous ointment (clinical drug) | This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. | Fluocinolone acetonide (substance) | true | Inferred relationship | Some | 1 | |
| Product containing precisely fluocinolone acetonide 250 microgram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release cutaneous ointment (clinical drug) | Has concentration strength numerator value | fem | false | Inferred relationship | Some | 2 | |
| Product containing precisely fluocinolone acetonide 250 microgram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release cutaneous ointment (clinical drug) | Is a | Product containing only fluocinolone and neomycin in cutaneous dose form (medicinal product form) | true | Inferred relationship | Some | ||
| Product containing precisely fluocinolone acetonide 250 microgram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release cutaneous ointment (clinical drug) | Plays role | Antibacterial therapeutic role (role) | false | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets
FHIR